Are you currently facing low expression yield, poor stability, and complexity in engineering next-generation biologics? Our Bispecific Fusion Proteins Generation Services help you achieve high-quality, manufacturable bi-functional drug candidates through Modular Domain Engineering and Optimized Expression Systems.
Contact our team to get an inquiry now!
Bispecific Fusion Protein (BsFP) is a major bispecific antibody format, defined as a therapeutic biologic generated by linking non-antibody proteins or functional domains to antibody fragments to add unique functionality or dual specificity. The source of these antibody fragments can be derived from single-chain variable fragments (scFv) or monospecific Fab dimers. The linker protein can be various functional entities, such as specific receptors of lymph cells (e.g., T cell, B cell, or macrophage), a second Fab molecule, or a strong and specific ligand of a receptor on tumor cells. This contrasts sharply with BsAb conjugates, as BsFPs are engineered and generated entirely by recombinant expression, ensuring homogeneity.
Creative Biolabs offers our clients multiple types of bispecific fusion proteins, including:
Fc fusion proteins are biotherapeutics that couple a protein of interest (e.g., an antigen or receptor antagonist) to the constant region (Fc) of an antibody, a design proven to significantly extend the drug's half-life in vivo.
Bispecific T-cell receptors represent a category of bispecific constructs founded on TCR principles. Their architecture incorporates two distinct elements: a modified TCR directed against cancerous cells and a functional single-chain fragment (scFv) specific to T-cell surface markers. This design enables the redirection of T-cell activity toward malignant targets.
To enhance the pharmacokinetic profile of compact bispecific entities, a common strategy involves conjugation with circulating plasma proteins like human serum albumin (HSA). This albumin-based fusion methodology has been applied to develop diverse bispecific antibodies, encompassing formats such as scFv-HSA-scFv, scDiabody-HSA, and tandem scFv-HSA.
BsAb-toxin fusions represent an advancement of immunotoxins, integrating a protein-based toxin (serving as the cytotoxic component) with an antibody segment. The predominant structure reported is the tandem scFv-toxin, alternatively termed bispecific ligand-directed toxin (BLT). Typically, enzymatic toxins like Pseudomonas exotoxin (PE) or diphtheria toxin (DT) are employed as the cytotoxic moiety.
This bifunctionality enables novel therapeutic strategies, such as T-cell redirection for cancer immunotherapy or simultaneous blockade of two disease-driving receptors. Furthermore, elements like human serum albumin or albumin binding proteins can be strategically fused to antibody fragments to extend their serum half-life in vivo. BsFPs have also been explored as a pre-targeting strategy for imaging and radioimmunotherapy. The complexity lies in fusing these non-IgG domains (like scFvs or enzyme domains) to an Fc region while maintaining stability and proper dimerization. Creative Biolabs' services provide the necessary precision engineering expertise to overcome these challenges, ensuring the resulting molecules retain high affinity, long circulation half-life, and excellent clinical potential.
Our Bispecific Fusion Protein (BFP) platform offers a versatile alternative to traditional bispecific antibodies. By fusing functional domains—such as cytokines, enzymes, or receptor extracellular domains—to antibody fragments (VHH, scFv, or Fab), we create multifunctional molecules capable of simultaneous target engagement and localized therapeutic action.
Whether you are developing Immunocytokines, Regulated Complement Inhibitors, or Dual-Targeting Decoy Receptors, our service provides a "one-stop" solution from in silico design to pilot-scale production. We specialize in optimizing the spatial orientation and linker flexibility of fusion partners to ensure maximum biological synergy and superior developability.
Choosing Creative Biolabs for your Bispecific Fusion Proteins Generation Services means partnering with a team that views complex engineering as a standard operating procedure. Our focus is on mitigating development risk before it leads to costly clinical delays. We leverage decades of expertise in protein biochemistry and optimized vector systems to ensure your construct is not only functional but inherently manufacturable.
Experience the Creative Biolabs Advantage - Get a Quote Today
A: Combining two mAbs often results in non-specific distribution and suboptimal stoichiometry at the target site. BsFPs are a single, defined molecular entity with fixed stoichiometry, ensuring both targets are engaged simultaneously by one agent. This allows for highly predictable pharmacokinetics (PK) and can achieve synergistic biological effects, such as T-cell redirection, that require a precise spatial arrangement of binding sites.
A: A significant challenge is ensuring efficient heterodimerization and preventing mispairing or aggregation, especially when using formats that deviate from natural IgG structure. Strategies to enhance stability involve rigorous linker optimization (to prevent domain-domain interference) and engineering the Fc domain using technologies like "knobs-into-holes" or electrostatic steering to enforce the correct dimeric association.
A: Format selection is driven by the desired mechanism of action (MoA), the required distance between the targets, and manufacturability concerns. Formats like scFv-Fc are often preferred for simpler production and T-cell engagement, while IgG-like formats offer a longer half-life and are structurally closer to native antibodies but present greater complexity in achieving correct chain pairing.
A: The timeline is dictated by the complexity of the molecular design and the requirements for expression and purification. Key variables include the need for extensive linker and domain screening during the design phase, the time required to establish high-titer transient or stable expression, and the complexity of the multi-step purification scheme needed to separate the desired heterodimer from homodimers and aggregates.
A: High yield and purity depend heavily on optimized expression vector systems and effective dimerization technology. Modern strategies utilize highly efficient mammalian expression hosts (CHO/HEK), coupled with genetic modifications (like knob-into-hole or electrostatic pairs) within the Fc region to drive heterodimer formation above 95%. Furthermore, tailored multi-step chromatography protocols are essential for separating the final product from structurally similar impurities.
Reference
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY
SERVICES
PRODUCTS
PLATFORMS
